Zenitar Biosciences Secures Nearly RMB 400 Million in Series B+ Financing Ahead of Hong Kong IPO Filing
Zenitar
Innovative Drug R&D and Industrialization Service Provider
Note:This article does not constitute any investment opinions or suggestions., subject to official/company announcements;This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprint requires authorization.
The funds from this round of financing will be mainly used to advance several innovative drugs with global competitiveness into pivotal Phase III clinical trials and support the continuous expansion of new R&D pipelines. Meanwhile, Zenitar will strengthen its three core technology platforms: the "Structural Biology Platform," the "AI-Driven Drug Design Platform," and the "Organoid-PDX Dual-Track Validation Platform." Leveraging these technology platforms, Zenitar is accelerating the development of an innovative drug pipeline featuring differentiated molecular scaffolds and novel targets, aiming to address unmet clinical needs.
The core candidate new drug of the company is Purinostat Mesylate (PM), the world’s first highly selective HDAC inhibitor used as a single agent in clinical trials for relapsed/refractory lymphoma. Currently, Purinostat Mesylate as a single agent has completed Phase I clinical trials for hematological tumors and Phase IIa/IIb clinical trials for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) in multi-center clinical trials across China. Simultaneously, Phase I/II clinical trials are also being conducted for T-cell lymphoma, solid tumors, and breast cancer.
Another candidate molecule is Flonoltinib Maleate (FM), a highly selective JAK2/FLT3/CDK6 triple-target inhibitor.
Pharmcube has learned that other targets under development include: PARP1, JAK3, NLRP3, molecular glue – for gastrointestinal tumors, etc.
Rooted in Shanghai and radiating globally, PharmaCircle, as a strategic platform for the biopharmaceutical industry, is on a mission to "enable the boundless flow of intelligence and connections." It has built an empowering system that covers the entire pharmaceutical industrial chain, including R&D, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource linking, industry think tanks, and ecosystem communities—it is creating the infrastructure for value flow within China's pharmaceutical sector.
Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources — it is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we are weaving a global network of pharmaceutical intelligence, making every precise connection a catalyst for enterprises' leapfrog growth.
